Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML)

被引：1
|
作者：
LeBlanc, Francis [1 ]
Bennett, Josh [2 ]
Choi, Kwangmin [3 ]
Starczynowski, Daniel T. [4 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH USA
[2] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
    Stahl, Maximilian
    Shallis, Rory M.
    Derkach, Andriy
    Goldberg, Aaron D.
    Stein, Anthony
    Stein, Eytan M.
    Marcucci, Guido
    Zeidan, Amer M.
    Shimony, Shai
    DeAngelo, Daniel J.
    Stone, Richard M.
    Aldoss, Ibrahim
    Ball, Brian J.
    Bewersdorf, Jan Phillip
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S209 - S210
  • [22] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [23] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [24] Continous exposure to methothrexate (MTX) overcomes resistance in childhood acute myeloid leukemia (AML) in vitro
    Rots, MG
    Zwaan, CM
    Pieters, R
    Kaspers, GJL
    Noordhuis, P
    van Zantwijk, CH
    Creutzig, U
    Peters, GJ
    Veerman, AJP
    Jansen, G
    PEDIATRIC RESEARCH, 1999, 45 (05) : 775 - 775
  • [25] Continuous Exposure to Methotrexate (MTX) Overcomes Resistance in Childhood Acute Myeloid Leukemia (AML) in Vitro
    M G Rots
    Ch M Zwaan
    R Pieters
    G J L Kaspers
    P Noordhuis
    C H Van Zantwijk
    U Creutzig
    G J Peters
    A J P Veerman
    G Jansen
    Pediatric Research, 1999, 45 : 775 - 775
  • [26] A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia
    Hu, Rong-Hua
    Su, Li
    Lan, Xiao-Xi
    Chang, Xiao-Li
    Hui, Wu-Han
    Guo, Yi-Xian
    Zhao, Hong
    Zhang, Yue
    Sun, Wan-Ling
    ANTI-CANCER DRUGS, 2023, 34 (03) : 344 - 350
  • [27] Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia
    Kobayashi, Takahiro
    Sato, Honami
    Miura, Masatomo
    Fukushi, Yayoi
    Kuroki, Wataru
    Ito, Fumiko
    Teshima, Kazuaki
    Watanabe, Atsushi
    Fujishima, Naohito
    Kobayashi, Isuzu
    Kameoka, Yoshihiro
    Takahashi, Naoto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 285 - 296
  • [28] Molecular and immunophenotypic predictors of response to azacitidine (aza) as frontline therapy for acute myeloid leukemia (AML).
    Zimmerman, Michael Keith Alister
    Grunwald, Michael Richard
    Symanowski, James Thomas
    Gerber, Jonathan Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia
    Sharon, David
    Chan, Steven M.
    MOLECULAR & CELLULAR ONCOLOGY, 2020, 7 (02)
  • [30] Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
    Vanttinen, Ida
    Saad, Joseph
    Ruokoranta, Tanja
    Kytola, Sari
    Ettala, Pia-Sofia
    Pyorala, Marja
    Rimpilainen, Johanna
    Siitonen, Timo
    Heckman, Caroline A.
    Kuusanmaki, Heikki
    Kontro, Mika
    BLOOD, 2024, 144 : 2757 - 2758
12345